We have investigated the purging efficacy of positive selection of autologous mobilized CD34
High-dose chemo/radiotherapy followed by autologous peripheral stem cell rescue might be a therapeutic modality to improve the prognosis of patients with high-risk neuroblastoma. 1 One concern using this approach is the possibility of reinfusing contaminating neuroblastoma cells, which may contribute to relapses post transplant. 2 Indeed, genemarking studies have shown that relapses after myeloablative therapy and autologous stem cell rescue can be caused by reinfused marked neuroblastoma cells. 3, 4 Therefore, purging techniques selectively removing the tumor cells without compromising the hematopoietic reconstitution capacity of the graft might be important to reduce the relapse rate after high-dose chemo/radiotherapy. Negative depletion techniques using a panel of different anti-neuroblastoma antibodies have been used in the past. 5 However, the heterogenous antigen expression of the target antigens in individual neuroblastoma patients might limit the purging efficacy of this method. 6 A more recently used purging method is positive selection of CD34 ϩ cells. 7 By positive CD34 ϩ cell selection, the heterogeneity of antigen expression on tumor cells does not play a role and positive CD34 ϩ cell selection can be used for purging for almost every tumor entity, as long as the tumor cells do not express the CD34 ϩ antigen. In order to achieve a high purging efficacy, the purity of the CD34 ϩ cells after positive selection must be very high. In our experience in 20 patients using mobilized peripheral stem cells and the CellPro method, we achieved a median purity of CD34 ϩ cells of 42% (range 4.3-76.6). 8 Due to this low purity, the median log depletion of neuroblastoma cells was only 1.41 (range 0.69-2.13). Using the Isolex 300 system, Leung et al 9 reported a higher purity of CD34 ϩ cells (median purity 92%, range 49-99%) after enrichment from mobilized peripheral blood in patients with high-risk neuroblastoma with a median tumor depletion of 3 log. A more recently described method for positive selection of CD34 ϩ cells, which allows the clinical isolation of CD34 ϩ to a very high purity is magnetic-activated cell sorting (MACS). [10] [11] [12] [13] In this paper, we describe the isolation of highly purified peripheral CD34 ϩ cells in 22 children with high-risk neuroblastoma and the purging efficacy using the MACS method.
Moreover, we show that the transplantation of the highly purified CD34
ϩ cells results in a rapid hematopoietic reconstitution after high-dose chemo/radiotherapy.
Patients and methods
Twenty-two patients with neuroblastoma (21 with stage 4, one with stage 3 and N-myc amplification) were analyzed. Before high-dose chemotherapy, all patients received standard chemotherapy according to the German National Protocol NB90 14 or NB97 15 for the treatment of high-risk neuroblastoma. In brief, the NB90 protocol is composed of two alternate chemotherapy cycles termed N1 and N2.
Cycle N1 is comprised of cisplatin (160 mg/m 2 ), etoposide (500 mg/m ). The median age and body weight of the children was 3.5 years (range 1.5-10.5) and 15 kg (range 8-37), respectively.
Peripheral stem cell mobilization and collection
The mobilization of hematopoietic progenitor cells was initiated in six patients with a single infusion of cyclophosphamide (4 g/m 2 ) followed by G-CSF (10 g/kg/day; Neupogen, Amgen, Thousand Oaks, CA, USA) and in 16 patients with a cytostatic regimen which was part of the treatment protocol followed by G-CSF. Leukaphereses were started during the hematopoietic recovery phase using a Fenwall CS3000 (Baxter, Round Lake, IL, USA) or a Cobe Spectra (Cobe Bct, Lakewood, CO, USA) cell separator.
Positive selection and enumeration of CD34
+ cells CD34 ϩ cells were purified from mononuclear cell products using either the SuperMacs/VarioMacs or the CliniMacs system (Miltenyi Biotec, Bergisch-Gladbach, Germany) as described by us. [11] [12] [13] Before and after separation, aliquots were taken for cell counts, viability staining with trypan blue, flow cytometric analysis of CD34 expression and the presence of GD2-positive neuroblastoma cells. The number of CD34 ϩ cells before and after positive selection and the purity post selection was determined using the ISHAGE guidelines. 16 Briefly, cells were stained with CD45-FITC and CD34-PE and dead cells were excluded with propidium iodide (Pl). The flow cytometric analysis was performed on a Facscalibur flow cytometer (Becton Dickinson, Heidelberg, Germany).
Detection of neuroblastoma cells
For the detection of neuroblastoma cells before and after positive CD34
ϩ cell selection, a direct immunofluorescence approach was chosen. Briefly, the chimeric antidisialoganglioside GD2 antibody delta ch 14.18 (kindly provided by Dr S Gillies, Lexigenpharm, Lexigen, USA) was directly labeled with FITC. Cells from the leukaphereses or after the Super/CliniMacs isolation were resuspended in PBS 2% FCS and the cell number adjusted to 3-6 ϫ 10 6 /ml. One ml of the cell suspension was removed, washed once and the cell pellet was resuspended in 0.1 ml. Five l of the prediluted FITC-labeled antibody were added and incubated for 30 min at 4°C in the dark. Cells were then washed twice with PBS and the cell pellet was then resuspended in 10 l of mounting medium, pipetted on to a microscope slide and covered with a coverslip. The proportion of positive cells was determined immediately after staining using a fluorescence microscope. A positive control with the GD2-positive neuroblastoma cell line LS and a negative control were run in parallel with each patient sample. The antibody delta ch 2 14.18 lack the Fc-binding portion ch 2 and has, in addition to a high affinity to GD2, a very low background staining. In spiking experiments, one neuroblastoma cell out of 10 5 mononuclear cells could accurately be detected (data not shown). The log 10 tumor depletion was calculated as described by Leung et al. 9 
Myeloablative therapy
Myeloablative chemotherapy consisted of melphalan (140 mg/m 2 ), etoposide (40 mg/kg) and carboplatin (1500 mg/m 2 ). In four of the patients, 300 mCi of meta[131] iodo-benzylguanidine (mIBG) therapy was given 1 week before the start of the chemoconditioning as described by us. 17 For reinfusion, isolated CD34 ϩ cells were rapidly thawed and injected without further washing. All patients received G-CSF (5 g/kg/day) starting day ϩ4 until a stable leucocyte count was reached. Supportive treatment included ondansetron, parental nutrition, prophylactic oral antibiotics, fluconazole and acyclovir.
Results

Isolation of CD34 ϩ cells and indirect depletion of neuroblastoma cells
A median number of 70 ϫ ). Out of the 17 patients whose leukaphereses showed contaminating neuroblastoma cells prior to positive selection, tumor cells could only be detected in four patients after positive selection. The median log depletion in these four patients was 2.05. In 13 out of the 17 patients, the tumor cell contamination post selection was below the detection limit of our method and no tumor cells could be detected in the graft. In these patients, the median minimum depletion was calculated based on our detection limit of 1:10 5 and was determined to be Ͼ3.0 log (range Ͼ2.0-4.4 log). The log depletion in these patients reflects a worst case scenario and might be an underestimation of the tumor cell depletion in these patients. These results and the remission status at time of leukapheresis are summarized in Table 2 .
Hematopoietic reconstitution after myeloablative therapy and clinical follow-up
Of the 22 patients, high-dose chemotherapy was performed in 18 patients. Three patients died due to progressive disease after stem cell collection and prior to autologous stem cell transplantation. One patient (patient No. 17) is alive in CR without stem cell transplantation. After infusion of the purified CD34 ϩ cells, a rapid hematopoietic reconstitution could be observed with a median time to Ͼ0.5 ϫ 10 9 /l ANC of 12 days (range 8-24 days). The median time to reach independence from platelet transfusions was 32 days (range 12-113 days). An adjuvant immunotherapy with the monoclonal antibody ch 14.18 was administered post transplant in 15 patients, as described by us. 18 Prior to autologous stem cell transplantation, only eight patients were in CR, whereas 10 patients were in PR or VGPR. After highdose chemotherapy, five of the 10 patients who were not in remission prior to transplant reached a CR and are alive without evidence of disease. Four of the eight patients who were in CR prior to transplant remained in CR. Six patients either relapsed or progressed and died, two patients are alive with relapse and one patient died due to secondary AML 10 months post transplant. These data are summarized in Table 3 . Kaplan-Meier analysis of the progressionfree survival was 54% with a median follow-up of 55 months (range 45-70 months) (Figure 1 ).
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Discussion
The treatment of high-risk neuroblastoma still remains one of the biggest challenges in pediatric oncology and the outcome with conventional therapy is poor. 19 One of the reasons for this bad outcome is the high relapse rate encountered in this malignancy. Myeloablative chemotherapy with autologous stem cell transplantation is increasingly used in patients who otherwise have a poor prognosis with standard chemotherapy alone. It is believed that myeloablative chemotherapy, eventually combined with mIBG radiotherapy 17 can eradicate residual tumor cells in CR patients, thus reducing the relapse rate. In non-CR patients post induction, therapy intensification with stem cell transplantation is used to overcome the resistance to conventional chemotherapy and to induce a CR in these patients. However, it has been shown in a number of studies, including our own, that the contamination of either bone marrow or mobilized peripheral stem cells is high. 9, 20 Even when the patients have no bone marrow involvement, contaminating tumor cells can be found. 21 After a lengthy scientific discussion about whether autografts, either bone marrow or PBSC, should be purged or not in neuroblastoma, convincing evidence has been shown by Brenner et al 22 that contaminating neuroblastoma cells cotransplanted with the graft can induce relapse post transplant. One of the original arguments against purging before the Brenner results were published was that the number of neuroblastoma cells present in an autograft is very low compared to the number of tumor cells present in the patient at time of transplantation, especially if the patient is not in CR when coming to transplant. However, the only intention of the ablative conditioning is to induce a CR in these patients. Given the gene marking data, a possible scenario is that a patient in PR or VGPR at time of transplant reaches a CR and will suffer from a relapse of cotransplanted neuroblastoma cells, which were not exposed to the high-dose chemo/radiotherapy. The same is, of course, valid for patients in CR at the time of transplant, since our study and others have shown that CR is a rather crude description of the tumor status of a neuroblastoma patient, and, in a number of CR patients with solid tumors or with hematological malignancies, minimal residual disease (MRD) can still be detected with more sensitive methods. 20 This is in line with our experience, since in four of our patients considered to be in CR at time of stem cell collection, a significant amount of neuroblastoma cells could be found in the graft prior to positive selection. In addition, circulating neuroblastoma cells have been found in 67% of newly diagnosed patients, thus underlining the tendency of this disease to dissemination. 23 Newer techniques for tumor cell detection, such as tumor cell enrichment prior to immunofluorescence or PCR, as described for melanoma, 24 will prove helpful in getting a better picture of the minimal residual disease status of a neuroblastoma patient.
In which patients should the autograft be purged? The tumor cell load present in a patient pretransplant will never be precisely known and the response to high-dose chemotherapy cannot be predicted for an individual patient. Prophylactic purging might not be helpful in a number of patients and the tumor cells present in this patient group at a Patients received standard chemotherapy according to the protocol NB90 or NB97, as described in Patients and methods. 3N1 refers to 3 cycles N1, 3N2 to 3 cycles N2. Stem cells were collected either after the last of these cycles or after cyclophosphamide given at the end of the standard chemotherapeutic regimen. b Calculated value based on the tumor detection sensitivity of 1:10 5 (as described in Patients and methods); numbers in bold show the tumor cells actually found in the graft after selection and the actual log depletion. ND = not detected; NA = not applicable.
Table 3
Remission status at time of transplant, tumor cell detection in graft, conditioning regimen, number of transplanted CD34 ϩ cells, hematopoietic reconstitution, post-transplant immunotherapy and follow-up the time of transplant might survive the myeloablative therapy and result in a relapse. However, in the patient group whose tumor cells do not survive the myeloablative regimen, a continuous and durable CR might be reached. Since we do not know which patients fall in which group at the time of autologous transplantation, it might be helpful to purge the autograft in every patient with high-risk neuroblastoma in order to minimize the risk of relapse.
Since a number of patients will not have the advantage of this strategy, it is important that the purging methods employed do not compromise the capacity of the graft to completely reconstitute hematopoiesis post transplant as fast as possible. Not all purging methods used in the past fulfilled these requirements. Methods such as chemopurging with 4-HC results in a long delay of hematopoietic reconstitution, possibly increasing the risk of transplantrelated mortality. 25 Negative depletion using monoclonal antibodies against neuroblastoma antigens are associated with a higher nonspecific cell loss depending on the cell processing techniques and might be less effective due to a heterogeneous antigen expression. 6 In addition, the antibodies used for tumor cell depletion might crossreact with CD34 ϩ cells, thus resulting in a possible co-depletion of CD34 ϩ cells.
26
A different approach for tumor cell depletion is the positive selection of CD34 ϩ cells. It has been shown that complete hematopoietic reconstitution can be achieved after myeloablative therapy in both the autologous and allogeneic setting. 12, 27 In order to obtain a good purging efficacy, the CD34 ϩ population should be as pure as possible. For patients with neuroblastoma, we have already described the feasibility and purging efficacy of peripheral stem cells using the CellPro method. 8 The mean CD34 ϩ purity was only 42%, the CD34 ϩ recovery was only 36% and the mean log depletion was 1.41. In order to increase the CD34 ϩ purity, we have used the SuperMacs/VarioMacs method. With this method, high purities and recoveries can be obtained. In our 22 patients, the median purity of CD34 ϩ cells was 97.6% with a CD34 ϩ recovery of 70% (data not shown). Of the 17 samples positive for tumor cells before selection, only four were still positive post selection. In 13
Bone Marrow Transplantation samples, the tumor cell contamination post selection was below the detection limit of our method.
The use of positive CD34 ϩ cell selection as a purging technique in neuroblastoma has been questioned by recent reports that some neuroblastoma cells might express the CD34 antigen, 28 thus leading to a co-enrichment of tumor cells with the progenitor cells. This might be a rather rare phenomenon, but we cannot exclude this possibility in our study. However, newer antigens expressed on pluripotent stem cells and not expressed on neuroblastoma cells, such as the recently described AC133 antigen, 29 will allow us to circumvent this problem by using AC133 as the target antigen for stem cell enrichment. Preliminary experiments have shown the feasibility of this approach (unpublished results). Since AC133 is only expressed on a subpopulation of CD34 ϩ cells, 30 an additional advantage of this approach would be a further reduction of the number of stem cells to be transplanted, resulting in a further indirect tumor depletion.
From our clinical experience, the transplantation of high numbers of CD34 ϩ cells does not significantly accelerate hematopoietic reconstitution and a safe and complete reconstitution was seen in all of our patients with lower numbers, some of them transplanted with only 1 × 10 6 /kg CD34 ϩ cells. However, no general recommendation can be given concerning lower threshold numbers, since these may differ according to the conditioning regimens used and techniques for cryoconservation. Every institution should be confident with its own lower threshold. Once such thresholds are known, the number of transplanted CD34 ϩ or CD133 ϩ cells can be limited to the range of this threshold, resulting in a further tumor depletion by reducing the number of reinfused cells.
The clinical outcome and long-term follow-up in our transplanted patients is promising. Nine of the 18 transplanted patients are alive and free of progression with a median follow-up of 55 months post transplant. Two patients are alive with relapse and one patient, who was transplanted in second CR died from secondary AML 10 months after the transplant while in remission of his neuroblastoma. The cause of death in all deceased patients was tumor progression or relapse, and no transplant-related death was seen. Most of the patients were treated post transplant with the anti-neuroblastoma antibody ch 14.18.
18
Although we do not know the influence of the adjuvant immunotherapy with the monoclonal chimeric anti-GD2 antibody ch 14.18 on the long-term survival in some of our patients, we conclude that combined therapeutic approaches including chemo/radiotherapy and adjuvant therapeutic strategies, such as retinoic acid 31 or monoclonal antibodies 32 might hopefully improve the outcome in patients with high-risk neuroblastomas. However, larger controlled trials have to be performed to verify this conclusion.
In summary, we showed that myeloablative chemo/radiotherapy followed by autologous stem cell transplantation, eventually in combination with post-transplant immunotherapy, is safe in patients with high-risk neuroblastoma and can be successful even if the patients do not reach a CR with standard chemotherapy. The method described in this paper using the MACS technology for the isolation of highly purified peripheral CD34
ϩ cells results in an effective indirect tumor depletion of the graft without compromising its capacity to completely reconstitute hematopoiesis after myeloablative chemo/radiotherapy.
